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In This IssueDon’t Forget a Chaperone
PAGE 1521
Fabry disease patients show a deficiency in the activity of the lysosomal enzyme a-galactosidase (a-GAL or a-Gal A). One proposed treatment
for Fabry disease is pharmacological chaperone therapy, where a small molecule stabilizes the a-GAL protein, leading to increased enzymatic
activity. Guce et al. show that the pharmacological chaperones 1-deoxygalactonojirimycin (DGJ) and galactose stabilize a-GAL and reveal
a biochemical basis for pharmacological chaperone therapy applicable to other protein misfolding diseases.
Overproducing Salinosporamide A
PAGE 1527
The chlorinated natural product salinosporamide A is a potent 20S proteasome inhibitor currently in clinical trials as an anticancer agent. To
deepen understanding of salinosporamide biosynthesis, Lechner et al. investigated the function of a pathway-specific regulatory gene, salR2,
and observed a selective effect on the production of chloroethylmalonyl-CoA. The ectopic overexpression of SalR2 under constitutive
promoter control was the key to selectively double the production yield of salinosporamide A without increasing the production levels of
its minor analogs, suggesting a unique mode of regulation of a biosynthetic precursor in polyketide assembly.TB Lipid Analysis Goes Big
PAGE 1537
Although tuberculosis remains a leading cause of death, detection of the causative mycobacterium in
patients remains slow and insensitive. Here Layre et al. report a mass spectrometry system for rapidly
detecting the diverse lipid molecules in mycobacteria that cause tuberculosis and databases that cate-
gorize the many lipid molecules in the cell wall. This system rapidly compares molecular content of any
two bacteria and allows the study of environmental and genetic effects. Additionally, improved platform
for lipid profiling enables rapid determination of the nature of the bacterium within a given patient.
DUBs Dirty Dozen
PAGE 1550
Intracellular fate of numerous proteins is regulated by ubiquitination, whereby small protein, ubiquitin (Ub),
or Ub chains are attached to the target. Additionally, cells have large number of deubiquitinating enzymes(DUBs), which hydrolyze Ub linkages. DUBs are a diverse family of enzymes, and Faesen et al. analyzed a dozen of enzymesmore narrowly clas-
sified as Ubiquitin-specific proteases (USPs) in order to deconvolute effect of regulatory domains and establish Ub chain preference. The study
provides insight in the biochemical behavior in the USP family and validates chemical tools that will be useful in characterizing other DUBs.
RaPID Means Business
PAGE 1562
Naturally occurring peptides often possess macrocyclic and N-methylated backbone. These features grant them properties suitable for drug
development. Because such peptides are generally found as natural products, it is still a formidable challenge in constructing novel libraries for
screening bioactivemolecules. Yamagishi et al. describe RaPID, a system for synthesizing a de novo library of ‘‘natural product-like’’ macrocyclic
N-methyl-peptides using translation machinery, coupled with an in vitro display. This system allows for rapid selection of strong binders against
therapeutic targets, as illustrated by selection of anti-E6AP macrocyclic N-methyl-peptides that strongly inhibit polyubiqutination of proteins.Dual Carbamoylations on Ansamitocin
PAGE 1571
Li et al. describe an interesting ansamitocinoside with carbamoyl substitution at the C-4 hydroxyl group of
the N-b-D-glucosylmoiety, which they identified from the ansamitocin producerActinosynnema pretiosum.
The carbamoylation of the glucosyl moiety was attributed to carbamoyltransferase gene asm21 gene
productAsm21.Thisenzymedisplayedpreference for18-O-methyl-19-chloroproansamitocinasasubstrate
formacrolactamC-7carbamoylation.However, Asm21exhibitedhigher catalytic efficiency towards theglu-
cosyl moiety. This work highlights curious enzymatic activity of anO-carbamoyltransferase performing dual
action on both a polyketide backbone and a glycosyl moiety during ansamitocin biosynthesis.
No More Proinvasive Crosstalk
PAGE 1581
Block the messenger! The tumor microenvironment is now acknowledged as a key regulator of cancer
progression. Jung et al. apply forward chemical genetics to the problem and discover heat shock protein 90 (Hsp90) as a potential drug target
to modulate cell communication within this microenvironment. This led to the characterization of triazine compound S06 as a promising drug
candidate for blocking Hsp90 function and cancer invasion.
A Map of the Antibiotic Resistance Kinome
PAGE 1591
To map the resistance kinase chemical space, Shakya et al. conducted a screen of 14 antibiotic resistance kinases against 80 protein kinase
inhibitors. This screen identified molecules with varied inhibition profiles, proving that protein kinase inhibitors offer privileged scaffolds with
the potential to block antibiotic resistance. For example, the flavonol quercetin inhibited a number of resistance kinases in vitro and in vivo. The
authors show that protein kinase inhibitors can be repurposed to block antibiotic resistance, providing leads for codrug design.Chemistry & Biology 18, December 23, 2011 ª2011 Elsevier Ltd All rights reserved v
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Much like a resistor in an electric circuit, a class of tetracyclic benzothiazepines, described here by Dong et al., blocks the flow of reduction
equivalents through the mitochondrial electron transport chain in the malaria parasite by specific inhibition of cytochrome bc1. Using a
transgenic parasite strain engineered to bypass the requirement of this otherwise essential mitochondrial machinery, in combination with
resistance selection and genetic mapping, the authors revealed the targeted pathway and pinpointed the molecular target of this previously
unexplored family of antimalarial compounds.vi Chemistry & Biology 18, DecembCa2+ Signaling Enters Synthetic Biosystems
PAGE 1611
Synthetic biosystems have been engineered to enable control of metazoan cell morphology, migration,
and death. These systems possess signal specificity but lack flexibility in choice of input signal. To
exploit the potential of Ca2+ signaling,Mills and Truong designedRhoA chimeras that enable reversible,
Ca2+-dependent control over RhoA morphology and RhoA-dependent migration. The Ca2+-activated
RhoA chimera demonstrated distinct activation patterns based on the spatial and temporal character-
istics of the input Ca2+ signal. Engineering synthetic biological systemswith input versatility and tunable
spatiotemporal responses are key motivations for further application of Ca2+ signaling in this field.
Glycolipids Wake Natural Killer T Cells Up
PAGE 1620Natural killer T (NKT) cells are a unique lymphocyte population that recognizes glycolipids presented by CD1d. The first antigen described, the
glycosphingolipid a-galactosyl ceramide (aGalCer), was derived from a marine sponge and is a potential anticancer agent whose activity
depends upon IFNg secretion. Structural variants of aGalCer are currently under development. Tyznik et al. synthesized different analogs
with an altered sphingoid base or fatty acid, based on glycosphingolipids found in various sponges. These elicit an increased proinflammatory
immune response characterized by high and sustained serum levels of IFNg and may be useful for cancer treatment. Immunology and
structural data suggest increased lipid-CD1d stability in vivo may be responsible for the enhanced secretion of IFNg.
VEGF-VEGFR Interface As a Clear Target
PAGE 1631
Combined in silico-in vitro screening studies were carried out over the vascular endothelial growth factor (VEGF)-VEGF receptor (VEGFR)
system, one of the flattest protein-protein interfaces available and a validated target for anti-angiogenic treatments. The approach allowed
Gaitier et al. to identify several low molecular weight compounds that bind to the receptor, inhibit the binding of VEGF, and thus block
a very challenging protein-protein interface.
New Cluster for New Polymyxin B-Type Antibiotics
PAGE 1640
Polymyxins are peptide antibiotics active against many species of drug-resistant Gram-negative bacteria. Shaheen et al. sequenced the gene
cluster for polymyxin biosynthesis from Paenibacillus polymyxa PKB1. The cluster codes for a peptide synthetase complex responsible for
making the polymyxin and two transporter proteins for moving the polymyxin out of the cell. Further analysis confirmed that P. polymyxa
PKB1 produces two novel forms of polymyxin B, which may have altered activity or toxicity properties compared to the original antibiotic.Aminoluciferins Shine Bright
PAGE 1649
Firefly luciferase-catalyzed light emission from D-luciferin is widely used as a reporter of gene expres-
sion and enzymatic activity both in vitro and in vivo. Despite the power of bioluminescence for imaging
and drug discovery, light emission from firefly luciferase is fundamentally limited by the physical prop-
erties of the D-luciferin substrate. Harwood et al. have previously synthesized aminoluciferin analogs
that exhibit light emission at longer wavelengths than D-luciferin and have increased affinity for lucif-
erase. Here, the authors describe mutant luciferases that exhibit improved and selective light output
with aminoluciferins in both lysed and live mammalian cells.
Mending a Broken Heart
PAGE 1658Ni et al. have discovered compounds able to induce cardiac cell generation and selectively promote cardiomyocyte formation without
affecting other tissue and organ development. The authors name the compounds Cardionogens and show that they act as antagonists of
Wnt signaling pathway. The finding demonstrates the benefits of a whole organism-based chemical screen and may open exciting avenues
for developing new therapeutics to replenish cardiac cells in diseased hearts.er 23, 2011 ª2011 Elsevier Ltd All rights reserved
